Target overview
Synonyms
HER2|ERBB2|HER-2
Emerging Competitive
HER2 / ERBB2
HER2 / ERBB2 is flagged as emerging competitive based on 100 active trials across 82 sponsors and 1 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 152
Active trials: 100
Recruiting trials: 54
Known assets: 1
Sponsor activity
Competitive footprint
Unique sponsors: 82
Top sponsors: DAIICHI SANKYO | Fudan University | National Cancer Institute (NCI)
Tumor types: Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
Patent-density signal summary
Patent layer
Signal count: 1
Recent signals: 1
Top assignees: AstraZeneca
Signal types: adc_composition
Scores and labels
Deterministic summary
Clinical crowding: 4/5 (High)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 1/5 (Low)
Momentum: 3/5 (Rising)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.